On December 16, 2021, Supriya Lifescience Limited to launch its initial public offer (IPO) which will be closed by December 20, 2021.
While preparing its DRHP (Draft Red Herring Prospectus) Supriya Lifesciences collaborated with CRISIL and Lifescience Intellipedia. The Lifescience Intellipedia was one of the data sourcing partner which has provided several data points related to the market details of the products which are there in Supriya Lifesciences portfolio. Supriya Lifesciences produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Supriya Lifesciences enjoys being the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. It is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume. More details are provided in the DHRP filed available at the link below.
DHRP Link: https://www.sebi.gov.in/filings/public-issues/may-2021/supriya-lifescience-limited_50137.html
Description: Chart
Description automatically generated
Pic 1: Sample Data Excerpts from DHRP data point
IPO Details: The offer price range has been set at Rs 265 to Rs 274 per equity share. Bids can be placed for as few as 54 stock shares and as many as 54 equity shares after that. The company intends to raise up to Rs. 7000 million in funding. The offer consists of a fresh issue of equity shares by the company worth up to Rs. 2,000 million (the "Fresh Issue") and an offer for sale by Satish Waman Wagh for up to Rs. 5,000 million. This Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (
